Viromed Medical AG Cash Flow Conversion Efficiency
Viromed Medical AG cash flow conversion efficiency. Based on the latest financial reports, Viromed Medical AG (Q11) has a cash flow conversion efficiency ratio of -0.038x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-10.12 Million ≈ $-11.83 Million USD) by net assets (€269.20 Million ≈ $314.72 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Viromed Medical AG (2021–2024)
Cash flow conversion efficiency of Viromed Medical AG from 2021 to 2024. This chart illustrates how Viromed Medical AG's cash flow conversion efficiency has evolved over time, based on yearly financial data. View latest Viromed Medical AG stock price today for real-time trading data and today's change.
Viromed Medical AG Cash Flow Conversion Ratio Explained
Viromed Medical AG cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Viromed Medical AG Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Viromed Medical AG ranked by their cash flow conversion efficiency. Also see Viromed Medical AG (Q11) total market value for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Everbright Jiabao Co Ltd
SHG:600622
|
0.042x |
|
Jereissati Participações S.A.
SA:IGTI3
|
0.010x |
|
Hinova Pharmaceuticals Inc. A
SHG:688302
|
N/A |
|
Surya Permata Andalan Tbk PT
JK:NATO
|
0.005x |
|
CanSino Biologics Inc
F:CJH
|
-0.079x |
|
Hua Eng Wire & Cable Co Ltd
TW:1608
|
0.026x |
|
Ausgold Ltd
AU:AUC
|
-0.012x |
|
Korea New Network Co. Ltd
KQ:058400
|
0.023x |
Annual Cash Flow Conversion Efficiency for Viromed Medical AG (2021–2024)
The table below shows the annual cash flow conversion efficiency of Viromed Medical AG from 2021 to 2024. Review Q11 free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €201.16 Million ≈ $235.17 Million |
€-6.03 Million ≈ $-7.04 Million |
-0.030x | +94.36% |
| 2023-12-31 | €64.28 Million ≈ $75.15 Million |
€-34.16 Million ≈ $-39.93 Million |
-0.531x | -60.96% |
| 2022-12-31 | €63.23 Million ≈ $73.92 Million |
€-20.87 Million ≈ $-24.40 Million |
-0.330x | +40.80% |
| 2021-12-31 | €39.97 Million ≈ $46.73 Million |
€-22.29 Million ≈ $-26.06 Million |
-0.558x | -- |
About Viromed Medical AG
Viromed Medical AG engages in the development and distribution of products in diagnostics, therapeutics, and cold plasma technology. The company was formerly known as Fonterelli SPAC2 AG. Viromed Medical AG was incorporated in 2021 and is based in Pinneberg, Germany.